Travere Therapeutics Insider Sold Shares Worth $258,278, According to a Recent SEC Filing
J.P. Morgan's Top Healthcare Stocks for 2025
Stifel Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $18
The 3.8% Return This Week Takes Travere Therapeutics' (NASDAQ:TVTX) Shareholders One-year Gains to 124%
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Insider Sale: SVP of $TVTX (TVTX) Sells 12,090 Shares
